Harrow Health Announces FDA Acceptance of New Drug Application for Ocular Pain Management

The FDA has accepted Harrow Health's new drug application (NDA) for AMP-100, the company's drug candidate for ocular surface anesthesia and intraoperative pain management during ocular surgery.

Harrow Health Announces FDA Acceptance of New Drug Application for Ocular Pain Management
February 23, 2022
Harrow Announces FDA Approval of Iheezo for Ocular Surface Anesthesia

Harrow and Sintetica SA jointly announced the FDA approval of Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia.

Harrow Announces FDA Approval of Iheezo for Ocular Surface Anesthesia
September 28, 2022
Outlook Therapeutics Announces FDA Acceptance of BLA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics announced that the FDA accepted for filing a Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration.

Outlook Therapeutics Announces FDA Acceptance of BLA for ONS-5010 as a Treatment for Wet AMD
October 31, 2022
More